Crossmark

Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease

Crossref DOI link: https://doi.org/10.1186/s12933-025-02741-5

Published Online: 2025-05-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Karuna, Narainrit

Kerrigan, Lauren

Edgar, Kevin

Ledwidge, Mark

McDonald, Ken

Grieve, David J.

Watson, Chris J.
Funding

Funding for this research was provided by:

Queen’s University Belfast

The Heartbeat Trust

British Heart Foundation (PG/20/10424)
License Information

Text and Data Mining valid from 2025-05-14

Version of Record valid from 2025-05-14
More Information

Article History

Received: 18 December 2024

Accepted: 14 April 2025

First Online: 14 May 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below